Investor Home

Corporate Profile

BeiGene is a commercial-stage biopharmaceutical company rooted in China that is dedicated to becoming a global leader in the discovery, development and commercialization of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.

We have three internally-developed late-stage clinical drug candidates:

  • Zanubrutinib (BGB-3111) — an investig...more >
Stock Quotemore >
BGNE (American Depositary Shares)

$167.12

0.00 (0.00%)

06/18/18  4:00 p.m. ET

Currency is USD
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Press Releasesmore >
BeiGene Provides Development Update and Presents Clinical Data on Zanubrutinib at the 23rd Congress of the European Hematology Association - June 15, 2018
Investor Call Scheduled Today, June 15, 2018, at 8:00 am EDT CAMBRIDGE, Mass. and BEIJING, China, June 15, 2018 (GLOB... Read More
BeiGene to Present at the Goldman Sachs 39th Annual Global Healthcare Conference - June 6, 2018
CAMBRIDGE, Mass., and BEIJING, China, June 06, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stag... Read More

Upcoming Events

There are currently no events scheduled.

E-mail Alerts

Sign up to receive e-mail alerts